Jun Miki

Associate Professor

Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (16)

Objectives Lymphovascular invasion (LVI) is an established adverse prognostic factor in urothelial carcinoma; however, prior studies have rarely distinguished lymphatic vessel invasion (LymVI) from blood vessel invasion (BVI). We investigated the prevalence and prognostic significance of LymVI and BVI in upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy (RNUx), and assessed their associations with clinicopathological characteristics and metastatic patterns. Methods We retrospectively analyzed 455 patients who underwent RNUx at Jikei University Hospital and six affiliated centers between 2012 and 2021. LVI subtype was assessed using hematoxylin–eosin staining, supplemented by D2–40, CD31, and Elastica van Gieson staining when required. Patients were categorized into four groups: no LVI, LymVI only, BVI only, and combined LymVI+BVI. Outcomes included non-urothelial tract recurrence–free survival (NUTRFS), cancer-specific survival (CSS), and overall survival (OS). Kaplan–Meier methods and Cox regression analyses were used to evaluate prognostic associations. Results LVI subtypes were distributed as follows: no LVI (65.1%), LymVI only (9.9%), BVI only (7.7%), and combined LymVI+BVI (17.4%). Higher pathological T and N stages were observed progressively across these groups (P < 0.001). BVI only and combined LymVI+BVI were independent predictors of inferior NUTRFS (HR 4.52 and 5.01), OS (HR 2.46 and 2.73), and CSS (HR 2.85 and 4.06), whereas isolated LymVI did not significantly affect outcomes. Hematogenous metastases to the lung, liver, and bone were significantly more frequent in patients with BVI or combined LVI. Conclusions Distinguishing BVI from LymVI provides refined prognostic stratification in UTUC. BVI, alone or combined with LymVI, is strongly associated with adverse survival and increased hematogenous dissemination, while isolated LymVI has limited prognostic impact. Routine pathological subclassification of vascular invasion may improve postoperative risk assessment and guide adjuvant treatment decisions.

Year:

2026

Objectives To evaluate the impact of age on treatment patterns and outcomes in patients with non‐metastatic castration‐resistant prostate cancer (nmCRPC). Methods We conducted a retrospective multicenter analysis of 428 patients with nmCRPC from 25 tertiary centers (2002–2022). Patients were divided into two age groups: < 80 and ≥ 80 years. The outcomes included cancer‐specific survival (CSS), overall survival (OS), and progression‐free survival (PFS). Results Among 428 patients (median follow‐up, 32.5 months), performance status (PS) 0 was more frequent in < 80 vs. ≥ 80 years (78% vs. 58%, p < 0.001). Use of first‐line androgen receptor signaling inhibitors (ARSIs) was similar (58% vs. 59%, p = 0.83) among all, whereas any‐line docetaxel use was less common in patients aged ≥ 80 years (33% vs. 9% for < 80 vs. ≥ 80, p < 0.001). Five‐year CSS was 76.5% vs. 63.7% ( p = 0.002) and five‐year OS 73.8% vs. 59.9% ( p = 0.006) for < 80 vs. ≥ 80 years, respectively. Time‐to‐treatment failure was shorter in patients aged ≥ 80 years ( p = 0.04). Conclusion Maintaining PS and managing ARSI‐related adverse events are essential in older patients with nmCRPC and may preserve their eligibility for chemotherapy and improve their prognosis.

Year:

2025

Introduction Enfortumab vedotin plus pembrolizumab (EVP) has shown promising efficacy in locally advanced or metastatic urothelial carcinoma (la/mUC), but real-world data in Japanese patients are limited. We assessed the safety and early efficacy of EVP, with a focus on cutaneous adverse events (AEs). Methods We retrospectively analyzed 48 Japanese patients with la/mUC treated with first-line EVP at 12 centers between November 2024 and March 2025. Clinical data, AEs, and tumor responses were collected. Cutaneous AEs were evaluated for onset, severity, and management. Tumor response was assessed using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Results The patients’ median age was 76 years, and 89.6% were cisplatin-ineligible. All patients experienced treatment-related AEs, with 39.6% having grade ≥3 events. Cutaneous AEs occurred in 60.4%, including 18.8% with grade ≥3 rash and two cases of Stevens–Johnson syndrome. The median time to discontinuation due to AEs was 14 days. The overall response rate was 39.6%, and the disease control rate was 69%, rising to 87% among 38 evaluable patients. Conclusion EVP demonstrated favorable early efficacy in Japanese patients but was associated with frequent early discontinuation due to AEs, particularly cutaneous toxicity. Early skin care and interdisciplinary management are essential. These findings support EVP use while emphasizing AE management and patient-centered care.

Year:

2025

Background To determine the optimal extent of pelvic lymph node dissection in bladder cancer, evaluating the prognostic relevance of nodal substaging, and assessing the feasibility of sentinel lymph node biopsy and omission of contralateral dissection. Methods This retrospective study included 180 patients undergoing laparoscopic or robot-assisted radical cystectomy. Sentinel lymph node detection was assessed in 30 cases as a pilot. The obturator region was defined according to lymphatic drainage patterns. The prognostic impact of nodal substaging was evaluated using Kaplan–Meier and Cox proportional hazards models. Laterality of tumor location and node metastasis was also analyzed. Results Sentinel lymph node biopsy demonstrated a 63% detection rate with a 1.6% false-negative rate. nodal metastases were observed in 8.9% of pN1 and 8.3% of pN2–3 cases, predominantly in the obturator region (87.5% and 100%, respectively). Lymph node metastases were most frequently located in the obturator region, including 87.5% of stage pN1 and 100% of stage pN2–3 cases. Cancer-specific survival was significantly better in pN1 than in pN2–3 cases (median 61 vs. 7 months, p < 0.001). Cox proportional hazards regression models identified pN2–3 as the strongest prognostic factor (HR for CSS: 25.4). Ipsilateral nodal metastasis was observed in 87.5% of lateral wall tumors. Conclusions Although sentinel lymph node biopsy demonstrated limited utility, the obturator region appears to represent the optimal diagnostic target for nodal metastasis. In pN1 disease, this region may be therapeutic, resembling sentinel nodes and showing limited spread with better prognosis than pN2-3 disease.

Year:

2025

Objectives To evaluate the efficacy and safety of bilateral vas deferens sutures in preventing postoperative inguinal hernia after prostatectomy for clinically localized prostate cancer. Materials and Methods This retrospective study included 282 patients with localized prostate cancer who underwent open or laparoscopic radical prostatectomy between July 2012 and July 2023. The inguinal hernia incidence rates were compared between the vas deferens suture group (141 patients, May 2017 to July 2023) and the control group (141 patients, July 2012 to April 2017). We further determined the risk factors for inguinal hernia after prostatectomy using a multivariate regression analysis. Results Among the 282 patients analysed, postoperative inguinal hernia was observed in 10 (7.1%) and 37 (26.2%) patients in the vas deferens suture and control groups, respectively. The incidence differed significantly between patients who did and did not undergo radical prostatectomy with a prophylactic procedure ( P = 0.006). The 2‐year inguinal hernia‐free rates were 93.4% and 85.1% in the vas deferens suture and control groups, respectively. The median duration for inguinal hernia development was 15 months. Multivariate analysis identified the vas deferens suture procedure as a single factor associated with protection against inguinal hernia development after radical prostatectomy (hazard ratio, 0.36; 95% confidence interval, 0.177–0.734; P = 0.005). Conclusions The vas deferens suture is a simple and safe prophylactic procedure to decrease the risk of inguinal hernia after radical prostatectomy.

Year:

2025

Objective To evaluate the cumulative incidence of medication‐related osteonecrosis of the jaw (MRONJ) in patients with prostate cancer and bone metastases receiving long‐term denosumab treatment, and also the occurrence of severe MRONJ and risk factors associated with the development of both MRONJ and severe MRONJ. Patients and Methods This retrospective study included 624 patients with prostate cancer and bone metastases treated with denosumab between January 2015 and December 2024. Patients without bone metastasis or with insufficient clinical data were excluded. The study assessed the cumulative incidence of MRONJ, as well as risk factors associated with MRONJ of any stage and severe MRONJ (Stage ≥2). Cox regression analysis was used to identify independent risk factors. Results The cumulative incidence of MRONJ at 1, 2, 3, and 6 years was 4.6%, 9.6%, 20.3%, and 51.9%, respectively. For severe MRONJ, the corresponding rates were 2.4%, 6.7%, 13.1%, and 27.9%, respectively. Multivariate analysis identified the following independent risk factors for MRONJ: extent of disease grade ≥3 (hazard ratio [HR] 2.00, P = 0.009), use of anticoagulants and/or antiplatelets (HR 2.08, P = 0.026), and a history of dental treatment within the past 6 months (HR 2.29, P = 0.003). Denosumab administration at intervals >1 month was associated with a reduced risk (HR 0.46, P = 0.041). Conclusion This study demonstrates that long‐term denosumab treatment in patients with prostate cancer and bone metastases is associated with a substantial cumulative incidence of MRONJ. Key risk factors were identified, along with a modifiable factor that may reduce risk. These findings suggest that adjusting denosumab dosing schedules could help mitigate MRONJ risk, underscoring the need for personalised treatment plans and early preventive strategies.

Year:

2025

Introduction Robot‐assisted surgery is increasingly utilized in urology, providing enhanced precision and potentially improving patient outcomes. The Saroa surgical system is a novel robotic platform featuring integrated haptic feedback and compatibility with standard laparoscopic instruments. This study reports the first clinical application of Saroa in robot‐assisted radical nephrectomy (RARN) and nephroureterectomy (RANU). Methods A single‐center, retrospective analysis was conducted on 11 patients who underwent RARN or RANU using Saroa between January 2024 and March 2025. Perioperative outcomes, complications, grasping force data, and Likert scale evaluations from surgeons and assistants were analyzed. Results All procedures were completed without conversion or major complications. No transfusions or Clavien–Dindo grade ≥ 3 complications occurred. Haptic feedback was associated with reduced grasping force (mean force: 2.94 N with feedback off vs. 0.49 N at 2.0× setting). Surgeons rated Saroa higher for haptic naturalness and grasp control, while overall satisfaction was greater with the da Vinci system. Assistants reported significantly greater technical engagement with Saroa ( p = 0.042), reflecting enhanced educational value. Conclusions RARN and RANU using the Saroa system appear safe and feasible, even in early clinical use. The system's compact design, tactile feedback, and cost‐effectiveness suggest potential for broader adoption and training utility. Further prospective studies are warranted to confirm its clinical and educational benefits.

Year:

2025

Background Few studies have provided a comprehensive analysis of sequential treatment strategies for locally advanced and metastatic urothelial carcinoma (la/mUC). This study assessed treatment patterns, prognostic factors, and optimal sequencing strategies in patients receiving first‐line platinum‐based chemotherapy (1 L‐PBC). Methods This retrospective, multicenter study analyzed 212 la/mUC patients who initiated 1 L‐PBC. Treatment sequences were categorized based on the therapy, including immune‐oncology (IO) drug and enfortumab vedotin (EV) therapy. Multivariate logistic regression identified risk factors for failing to progress to EV therapy. Results The median follow‐up duration was 17 months. Of the 212 patients, 65 (38.9%) progressed to EV therapy, achieving the longest median overall survival (OS) of 41 months, compared to 25 months in the 1 L‐PBC + IO group and 8 months in the 1 L‐PBC group. Poor performance status (ECOG‐PS ≥ 1), age ≥ 80 years, and elevated levels of C‐reactive protein (≥ 1) were significant predictors of failing to reach EV therapy. Kaplan–Meier analysis indicated no survival difference based on avelumab use in patients with no risk factors, but patients with one or more risk factors receiving avelumab had significantly longer OS than patients who did not receive avelumab. Conclusions This study emphasizes the prognostic importance of achieving EV therapy and the role of maintenance avelumab in improving outcomes for la/mUC patients with one or more risk factors after 1 L‐PBC. Combining EV with pembrolizumab is a promising first‐line treatment, and 1 L‐PBC remains a viable option for selected patients.

Year:

2025

Background: Assessing the quality of surgical procedures is crucial for improving outcomes in radical cystectomy (RC). While the “Pentafecta” metric has been used, its reliance on the absence of local recurrence within 1 year delays postoperative assessment. For timely clinical decision-making, a new metric that facilitates earlier evaluation is needed. We propose such a metric, named Trifecta. We evaluated its impact on prognosis and identified predictors for achieving it. Methods: The Trifecta metric was defined as meeting three criteria: adequate lymphadenectomy (≥10 nodes), negative surgical margins, and absence of Clavien-Dindo grade 3–5 complications within 30 days after surgery. This retrospective study analyzed data from patients who underwent RC and lymphadenectomy between April 2014 and June 2024. Kaplan-Meier analysis was used to assess oncological outcomes, including intrapelvic recurrence-free survival (RFS), metastatic-free survival (MFS), cancer-specific survival (CSS), and overall survival (OS). Cox proportional hazards models were used to examine the association between Trifecta and these outcomes, while logistic regression was used to identify predictors for failing to achieve Trifecta. Results: Of the 196 patients included, 121 (61.7%) achieved Trifecta and this was significantly associated with improved intrapelvic RFS, CSS, and OS but not MFS. Low serum levels of albumin were identified as a significant predictor for not achieving Trifecta. Conclusion: Achieving Trifecta was associated with improved survival outcomes, and low serum levels of albumin predicted a higher likelihood of failure to achieve it. The Trifecta metric enables early and clinically relevant evaluation of surgical quality, offering a practical alternative to traditional metrics.

Year:

2025

Introduction The biology of castration‐resistant prostate cancer (CRPC) status between conventional hormonal therapy and upfront androgen signaling inhibitor (ARSI) treatment might be different, and the biological status of prostate cancer after failure of sequential ARSI in conventional hormonal therapy would be the same as CRPC in upfront ARSI. In this study, we evaluate our proposed definition of CRPC in our cohort with propensity score‐matched analysis. Patients and Methods A total of 885 patients diagnosed with metastatic hormone‐sensitive prostate cancer (mHSPC) who received conventional hormonal therapy, upfront androgen receptor signaling inhibitors (ARSI) with or without docetaxel therapy at Jikei University Hospital and its affiliated institutions, were included in this study. We compared survival outcomes between conventional hormonal therapy and upfront ARSI doublet treatment using conventional CRPC definition or our proposed CRPC definition. Result CRPC‐free survival (CRPCFS) and cancer‐specific survival (CSS) is significantly better in upfront ARSI (upfront (+)) than upfront (–) group (median CRPCFS is 68 months vs. 18 months, median CSS is not reached (NR) and NR, ( p < 0.0001 and p = 0.0381), respectively) in propensity score‐matched cohort, although overall survival (OS) is not different. Median CSS and OS after conventional CRPC diagnosis is NR (upfront (–)) and 30 months (upfront (+)) ( p = 0.0614), and 37 months (upfront (–)) and 24 months (upfront (+)) ( p = 0.00503). OS is significantly better in upfront (–) than upfront (+) group with conventional CRPC definition. Median CSS and OS after our proposed CRPC diagnosis is 20 months (upfront (–)) and 30 months (upfront (+)) ( p = 0.389), and 20 months (upfront (–)) and 24 months (upfront (+)) ( p = 0.932). Conclusion This proposed CRPC definition is thought to reflect the actual biological characteristics of prostate cancer with or without upfront ARSI treatment, and it is thought that the introduction of this definition should be considered when comparing the survival outcome between with or without upfront ARSI treatment.

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2022

Collaborators (7)

Mori Keiichiro

assistant professor

Jikei University School of Medicine

JAPAN
View details

Yuta Yamada

Associate Professor

University of Tokyo

JAPAN
View details

Yuto Matsushita

Hamamatsu University School of Medicine

JAPAN
View details

Yoshiki Asayama

professor and chairperson

Oita University

JAPAN
View details

Taro Igarashi

assistant professor

Jikei University School of Medicine

JAPAN
View details

Takuma Kato

Kagawa University

JAPAN
View details

Takahiro Kimura

Jikei University School of Medicine

JAPAN
View details